Last updated on December 2017

A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease

Brief description of study

The primary objective is to evaluate the effects of administration of neflamapimod (VX-745) for 24-weeks on immediate and delayed recall aspects of episodic memory, as assessed by the Hopkins Verbal Learning Test – Revised (HVLT-R) in subjects with mild Alzheimer’s disease (AD).

Clinical Study Identifier: TX155156

Contact Investigators or Research Sites near you

Start Over

Arifulla Khan, MD

Northwest Clinical Research Center
Bellevue, WA USA
  Connect »